BioCentury
ARTICLE | Clinical News

CS055: Phase I started

October 4, 2010 7:00 AM UTC

Huya began a U.S. Phase I trial to evaluate oral HBI-8000. Huya has exclusive rights from Shenzhen Chipscreen to the compound outside of China, where the companies are co-developing the compound (see ...